By Colin Kellaher
Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the sidelines of the booming obesity market.
Shares of the New York company, which closed Friday at $21.91, were recently down 1.9% at $21.50 in premarket trading.
Pfizer said the move follows a review of the program's clinical data, including the case of a single participant in a dose-optimization study who experienced a potential drug-induced liver injury that resolved after discontinuing danuglipron.
Pfizer previously ended a study of a twice-daily version of danuglipron after disappointing trial results in which there were too many side effects.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 14, 2025 06:54 ET (10:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。